Hair Removal — Evidence Map

Yes (brown/black on most skin): laser is viable. Pick the wavelength by skin Fitzpatrick (§05).
No (blonde, red, grey, white): laser fails — no chromophore. Electrolysis is the only reliable permanent option. Eflornithine slows growth but does not remove. Do not let a laser clinic sell you a course on blonde/grey hair — it won't work and paradoxical induction on face/neck is a real risk.

Fitz I-III (fair → olive that tans): alexandrite 755 nm or diode 810 nm. Both excellent.
Fitz IV (light brown, Mediterranean, South/East Asian, Latin American): diode in SHR mode or Nd:YAG. Alex only with an operator who knows how to drop fluence and add cooling.
Fitz V-VI (brown to darkest brown/Black): long-pulse Nd:YAG 1064 nm is standard of care. Short-wavelength lasers on dark skin cause 19% PIH in published series vs 2-3% with Nd:YAG. Walk out if the clinic only has an alexandrite for Fitz VI.

70-90% density reduction acceptable, dark hair: laser course (6-12 sessions). Cheaper, faster, modally the right answer.
Definitive clearance required (pre-vaginoplasty genital, single hairs on a mole, survivor ingrowns, grey/white/blonde residuals, paradoxical hypertrichosis from prior laser, fine facial vellus): electrolysis, with blend or galvanic depending on follicle depth and curvature.
Temporary maintenance: shaving, waxing, sugaring, threading. Do not expect permanent reduction from these; the "years of waxing thinned my hair" effect is mostly telogen-stage appearance, not follicle destruction.

Selective photothermolysis (SPTL): if you pulse light at a wavelength strongly absorbed by one target (chromophore) but weakly by surrounding tissue, and your pulse is shorter than the target's thermal relaxation time, the target heats before heat can diffuse out — you get confined thermal damage. Every modern laser hair removal, vascular laser, tattoo laser, and pigmented-lesion laser descends from this paper.

For hair: chromophore = melanin (eumelanin ≫ pheomelanin) in the hair shaft and matrix. Target = the bulge stem cells and dermal papilla, which aren't pigmented themselves — heat conducts from the pigmented shaft outward to them. Bulge cells can survive sub-lethal exposures, which is why the outcome is "permanent reduction," not eradication. Some follicles regenerate from surviving stem cells.

Anderson & Parrish 1983 Science PMID 6836297; Altshuler & Anderson 2001 Lasers Surg Med PMID 12030874.

Pheomelanin (red/strawberry blonde) absorbs weakly at 755-1064 nm. Grey and white hair have near-zero melanin. Without absorption there's no heating, without heating there's no follicular destruction — the laser pulse goes through cleanly. Liposomal-melanin augmentation products (e.g., Lipoxôme) tried to seed the shaft with melanin externally; trials have been disappointing (~14% reduction at 6 months).

Inui & Itami; Koenig 2007 Lipoxôme PMID 17452842.

First laser used for hair removal in the 1990s (Grossman 1996). Strong epidermal melanin absorption caused hypopigmentation even in Fitzpatrick II. Mostly retired from commercial practice; you will essentially never see this machine today. Mentioned for historical completeness and because it occasionally surfaces in old literature comparisons.

Strong melanin affinity, shallow-to-moderate penetration. Best wavelength for Fitzpatrick I-III dark hair. 2001 Lloyd/Eremia long-term series showed 73-79% reduction across Fitz I-III. DCD cryogen cooling is nearly always paired with it on Candela platforms.

Long-term reduction (Husain 2022 meta-analysis): 35-84% depending on protocol

Lloyd/Eremia 2001 PMID 11737124; Husain 2022 PMID 35634805; Candela GentleMax product docs.

Deeper penetration than alex, versatile across Fitzpatrick I-IV, can be pushed to Fitz V in SHR mode. LightSheer DESIRE's HS vacuum-assist handpiece runs at lower fluences (4.5-12 J/cm²) for comfort; XC handpiece runs high-fluence contact-cooled (10-40 J/cm²). Williams 2023 network meta-analysis found diode significantly better than control at 3 and 6 months and no class clearly superior overall.

Long-term reduction: 32.5-69.2% (Husain 2022)

Lumenis LightSheer docs; Williams 2023 PMID 37493187; Husain 2022.

Longest wavelength in routine LHR use → deepest penetration, lowest epidermal melanin absorption. Safest for Fitzpatrick V-VI because the hair shaft deep in the dermis still absorbs enough while the melanin-rich surface skin is relatively transparent at 1064 nm. Alster 2001/2003 and later studies document 80-90% density reduction with minimal AEs in dark skin.

PIH ~2-3% with Nd:YAG on Fitz V-VI vs up to 19% with shorter wavelengths

Trade-off: less efficient on light/fine hair. More sessions needed per density reduction than alex/diode on light skin. Some clinics use it as "safety wavelength" even on Fitz IV.

Alster 2001; Ibrahimi 2011 PMID 21519944; Battle 2002/2004 PMID 14725660.

Xenon flashlamp with optical filters setting the lower cutoff (515, 590, 640, 695, 755 nm). Non-coherent, polychromatic → less chromophore-specific than a laser. Larger spot size and multi-indication (vascular, pigmented, acne). Dorgham 2020 meta-analysis in skin of colour: alex > IPL on count reduction; diode and Nd:YAG comparable to IPL; Nd:YAG favoured for PIH avoidance.

Generally less efficient than a matched laser per session

Dorgham 2020 PMID 31587390; Haedersdal 2006 Cochrane CD004684.

Emits 755, 810, and 1064 nm simultaneously through one handpiece. Marketed as "one device for all Fitzpatrick types" — mechanistically plausible (different depths, different melanin absorption). Independent head-to-head RCTs vs single-wavelength gold standards are thin; most evidence is manufacturer-sponsored or open-label. Reasonable in a busy practice; not definitively superior to a matched single-wavelength device.

Alma Soprano product documentation; small independent comparative studies.

Only anagen (actively growing) follicles respond reliably — the melanin gradient is highest and the shaft is physically connected to the papilla. ~10-20% of follicles are in anagen at any moment; the rest are in telogen/catagen and won't be targeted at this visit. Spacing lets the next cohort cycle into anagen.

• Face / hormonally-active: 4-6 weeks (shorter cycle ~6 mo).
• Trunk, limbs: 6-10 weeks.
• Legs: 8-12 weeks (longest cycle ~12 mo; also best long-term reduction).
• Total course: 6-12 sessions typically. Many patients need 8-12+.
• Expected clearance: 70-90% terminal hair reduction at course end. Not eradication. Touch-ups every 6-24 months common.

Leg hair shows greatest long-term reduction · facial hair shows the least · blame hormones

• No plucking / waxing / threading / epilating for 4+ weeks prior. These remove the chromophore target. Shaving is fine and required day-of (12-24 h prior).
• No UV / self-tanner 4-6 weeks pre and 2-4 weeks post. Tanned epidermis competes for absorption → burns / dyspigmentation.
• Retinoids off 3-7 days pre and post.
• Isotretinoin: ASDS 2017 (Waldman) — the old 6-month wait is not evidence-based for non-ablative laser hair removal. 1485 procedures reviewed, no signal of harm. Many clinics still impose it conservatively. Waxing is still a higher-caution subset.
• HSV prophylaxis (valacyclovir 500 mg BID × 10-14 d) if known orofacial/genital HSV and the treatment area includes lips or genitalia.

Waldman ASDS 2017 PMID 28498204; Beeson & Rachel 2002 PMID 11966791 (valacyclovir resurfacing RCT).

Instead of reducing hair, a treatment area becomes denser with newly-terminal hairs. Most often on face, neck, and jawline. Incidence is wide: classically quoted 0.6-10%; a 2024 prospective study found 0.34% overall; 2025 series report ~3-5% on face. The variance reflects population mix, wavelength choice, and subthreshold fluences.

Proposed mechanism: subthreshold fluence stimulates dormant (telogen) vellus follicles, synchronises hair cycling, and/or induces vellus→terminal conversion via inflammatory cytokines. Not proven; the bulk of evidence is circumstantial.

Who's at risk: alexandrite and IPL are most implicated (Nd:YAG least). Fitz III-IV with Mediterranean, Middle Eastern, or South Asian ancestry. Female, facial/neck region (jawline most commonly). Underlying PCOS or hyperandrogenism. Some 2025 data show a higher incidence in men on face; interpret cautiously.

Desai 2010 PMID 20100274; Moreno-Arias/Desai 2021 PMID 34057666; Moriguchi 2025 PMC12040530.

Documented ocular injuries from periocular LHR include iris atrophy (65% of reported cases), anterior uveitis (60%), posterior synechiae, pupillary distortion, cataract, and (for Nd:YAG) retinal hemorrhage. The laser beam does not need to hit the eye directly; reflected and transmitted components are enough. Lerner 2017 case series: 34/40 injured patients wore no eyewear; 5 wore non-wavelength-specific goggles.

Lerner 2017 PMC5843357; Lin et al JAMA Ophthalmol; Shulman 2011 PMC3245195.

FDA classifies electrolysis epilators as Class II devices. Electrolysis is the only hair-removal modality legally marketable as "permanent hair removal" in the US. Laser is "permanent hair reduction." In practical terms, electrolysis is the per-follicle definitive method used when hair colour, follicle distortion, or surgical requirements make reduction alone insufficient.

The 2022 Salibian/Zhang vaginoplasty-prep comparison is the modern operational reality check: electrolysis reached the endpoint, but with far more hours, pain burden, and cost than laser when dark hair made laser possible. That does not make electrolysis obsolete. It explains why laser is usually the bulk-reduction step and electrolysis the finishing or nonpigmented-hair step.

Salibian/Zhang 2022 PMC9537259; FDA 21 CFR 878.5350; AMA CPT 17380.

US state licensing for electrology ranges from zero required training to 1,100+ hours. ~32 states license; ~18 do not. The national CPE (Certified Professional Electrologist) is voluntary, administered by AEA via IBEC/Prometric, 75 CEU per 5-year renewal.

Why this matters more than for laser: laser is a pulse delivered at distance with strong machine cues. Electrolysis requires manual insertion to correct depth at correct angle into the correct follicle, with dose selection (units of lye, or RF watts × time) tuned live to hair coarseness and skin reactivity. A poorly-trained electrologist either under-treats (high regrowth, wasted hours) or over-treats (scarring, dyspigmentation). Wagner 1985 JAAD explicitly flagged state-licensing non-uniformity as a public-health gap.

AEA/IBEC CPE documentation; Wagner 1985 JAAD PMID 3989007.

Physics: DC current 0-3 mA through a probe (cathode) inserted to follicle depth; patient holds the anode. Follows Faraday's laws — NaOH produced ∝ current × time. The trade unit is "units of lye" = mA × seconds × 10 (manufacturer-normalised).

Chemistry at the cathode: 2 NaCl + 2 H₂O → 2 NaOH + H₂↑ + Cl₂↑. A bolus of hydroxide ion plus nascent hydrogen saponifies follicular epithelium and the dermal papilla. Cold chemistry — no heat. The slow speed (20 s - 2 min per hair) is the dose window for enough NaOH to form and diffuse.

Origin: Charles E. Michel, St. Louis ophthalmologist, published in St. Louis Medical and Surgical Journal, 1875 — originally for trichiasis (ingrown eyelashes) using a sewing needle wired to a battery. The first hair-removal technique with any claim to permanence.

Hinkel & Lind 1968; Richards & Meharg 1995 PMID 7673501.

Physics: high-frequency AC, 13.56 MHz standard (FCC ISM band, same slot as RFID). Output 0-8 W. Tissue water dipoles oscillate; resistive loss heats follicle tissue to ~48-50 °C → protein coagulation of matrix and papilla. Heat radiates outward in a teardrop/pear pattern from probe tip — depth and angle errors produce surface burns.

Operator skill dependence is steep because the thermal pattern is less forgiving of depth/angle error than galvanic chemistry — you're heating a teardrop volume, not just at the tip. Wagner, Flores & Argo 1994 showed EMLA 5% significantly reduces upper-lip thermolysis pain (VAS paired t-test p=0.0001, n=30).

Origin: Henri Bordier, Lyon, 1924 — high-frequency diathermy for hypertrichosis. Flash variant came later (1940s-60s commercial machines).

Hinkel & Lind 1968; Wagner et al 1994 JDSO PMID 8113509; Richards & Meharg 1995.

Physics: sub-galvanic-threshold DC accelerated by RF-induced heat. Arrhenius speed-up ~2× per 10 °C means a warm galvanic reaction runs far faster than a cold one. Net: galvanic-grade destruction at a fraction of galvanic time.

Richards & Meharg (1995 JAAD, 140,000 hours of practice, PMID 7673501) concluded blend > galvanic > thermolysis on permanence. Scarring does not occur with properly performed electrolysis. 1-5 days of shaved regrowth before a session ensures anagen targeting. This is a large open series, not an RCT — C3 — but it's the closest thing to a consensus efficacy document in the field.

Origin: Arthur Hinkel + Henri St. Pierre, bench 1945; US patent 2,444,173 granted 1948. Hinkel & Lind's textbook Electrolysis, Thermolysis and the Blend (1968) remains the clinical foundation.

Richards & Meharg 1995 PMID 7673501; 1997 textbook; Hinkel & Lind 1968.

10-32 needles (16-needle units typical, GEMM-16 / EPX-16 / Instantron) inserted in parallel as galvanic cathodes, each drawing low DC; they reach treatment dose at slightly staggered times and the operator sequentially withdraws them. The pitch is high-volume clearance — trans pre-op, hirsutism, full-face clearance — without the per-hair time penalty of single-needle galvanic.

Throughput: best case ~600 hairs/hr on cheek using two machines; realistic upper lip / neck 100-200 hairs/hr. Concentrated in Southern California, some NYC and Toronto shops.

Shaving does not make hair grow back thicker, darker, or faster. Classic experiments — Lynfield 1970 J Invest Dermatol, Saitoh 1967, Trotter 1928 — measured hair weight and width before and after sustained shaving; no change. The blunt-tip illusion is because shaved stubble has a cut cross-section (wider silhouette) instead of a natural tapered tip. The follicle does not produce more keratin in response to being shaved.

Regrowth rates: terminal scalp/beard ~0.27-0.44 mm/day (~1 cm/mo); leg/axilla ~0.21-0.27 mm/day. Stubble visible in 1-3 days. Multi-blade razors cut below the skin surface by hysteresis (first blade lifts the hair, subsequent blades cut it below) — this below-surface cut is the direct cause of PFB (§22) in curly-haired populations.

Lynfield & MacWilliams 1970 PMID 5468232; Saitoh 1967; Trotter 1928.

Waxing: resin (strip) or synthetic polymer (hard/film wax) adheres to hair, pulled off against growth; entire shaft including bulb (in anagen) removed. Regrowth 2-6 weeks (face 2-3, leg 3-6). Hard wax adheres more to hair than skin — preferred for sensitive zones. Sugaring: sucrose-lemon-water paste, water-soluble, room/body temperature (no burn risk), removed in direction of hair growth. RCT-grade evidence for sugaring's "less painful / less trauma" claim is thin; most is practitioner survey.

Olsen 1999 JAAD PMID 9922008; Khunger & Sarkar 2008; ASPS isotretinoin advisory.

Twisted loop of cotton thread rolled across skin; hairs caught in the twist and pulled at the root. South Asian / Middle Eastern / Central Asian origin. Mechanism identical to plucking but faster and more precise; used for brows, upper lip, jawline. Regrowth 2-4 weeks. AEs: folliculitis, PIH (Fitz IV-VI), rare molluscum/verruca transmission via shared thread, koebnerisation of vitiligo or lichen planus.

Verma 2009 Int J Dermatol PMID 19416375; Abdel-Gawad 2012 Dermatol Surg.

Calcium/sodium/potassium thioglycolate (pH 10-12.5) reduces disulfide bonds in hair keratin (cystine → cysteine), dissolving the shaft at or just below skin surface. Follicle is untouched. Regrowth 2-7 days — slightly slower than shaving because the shaft breaks a fraction of a millimetre below the surface.

Magic Shave and similar powdered barium-sulfide products are popular in Black men for PFB management specifically because hair breaks at/above the surface rather than from a below-surface sharp tip — no re-entry lesion.

Draelos Cosmetic Dermatology; FDA MedWatch reports.

Mechanical single-hair removal (tweezer) or automated pinching (Braun Silk-épil, Philips Satinelle, Emjoi). Regrowth 2-8 weeks. Repeated plucking can cause focal scarring and distorted regrowth; permanent follicle destruction is inconsistent (Lanigan 2001). Not a hair-removal strategy — a side effect.

Olsen 1999; Lanigan & Felton 2001; Dierickx 2000 Dermatol Clin.

FDA-cleared under 510(k) for "permanent hair reduction" — a lower bar than clinic lasers, but the wording is the same. Two classes:

• IPL-based: Philips Lumea Prestige / 9000 / Advanced, Braun Silk Expert Pro 5, Silk'n Infinity, Nood Flasher 2.0, Ulike Air 3/10 (IPL despite "laser" branding), JOVS Venus Pro. Broadband xenon-flashlamp, filters, skin-tone sensor lockouts on darker skin.
• True diode laser: Tria Beauty Hair Removal Laser 4X — the only FDA-cleared home diode (~810 nm). Smaller spot, higher per-pulse energy than IPL, slower coverage, Fitz I-IV only.

Fluence gap: home 3-10 J/cm² vs clinic 15-30+ J/cm²

Evidence: Alster & Tanzi 2009 (Silk'n SensEpil, n=30) 37-60% reduction at 6 mo. Trelles 2012 (Philips Lumea, n=20-27) 47-60% at 3 mo, regressing after stopping. Mulholland 2009 (Tria 4X, n=49) ~60% at 6 mo. Thaysen-Petersen 2012 review: most effect regrows substantially by 12 mo post-regimen. Effect is real but modest, and often requires indefinite maintenance.

Alster & Tanzi 2009 Dermatol Surg PMID 19187179; Trelles 2012 PMID 22276783; Mulholland 2009 Clin Plast Surg.

Mechanism: α-difluoromethylornithine (DFMO) is an irreversible "suicide" inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine synthesis (putrescine → spermidine → spermine). Polyamines are required for hair-follicle keratinocyte proliferation. Blocks growth of the shaft without killing the follicle.

Evidence: FDA approval 2000 based on two 24-week vehicle-controlled RCTs (n≈594 women with unwanted facial hair). "Marked improvement / clear or almost clear" PGA endpoint — ~32-38% eflornithine vs ~8-9% vehicle at week 24. Benefit detectable by week 8. Effect plateaus; growth returns to baseline in ~8 weeks after stopping.

Additive to laser: Hamzavi 2007 split-face RCT n=54 — 93.5% success vs 67.9% laser alone at 34 wk

Use: BID application (≥8 h apart); visible effect 4-8 weeks. US cost $50-150 per 30 g tube, typically not insurance-covered. AEs: acneiform eruption ~7-11%, stinging ~8%, folliculitis ~1%. No systemic absorption concern (topical plasma <1% of oral trypanosomiasis dose).

FDA Vaniqa label 2000; Shapiro & Lui 2001 JAAD PMID 11511817; Hamzavi 2007 JAAD PMID 17482708.

Aldosterone antagonist with off-target AR antagonism and weak 17α-hydroxylase inhibition. Off-label hirsutism/PCOS dose 50-200 mg/day (modally 100 mg). Ferriman-Gallwey score reduction ~15-40% at 6-12 mo. Comparable to finasteride 5 mg in head-to-head; superior to flutamide 250 mg in some.

Safety: hyperkalemia risk mostly in renal impairment, ACE-I/ARB users, high-K diet. Plovanich 2015 JAMA Dermatol showed routine potassium monitoring in young healthy women on spironolactone is low-yield. Menstrual irregularity common (mitigated by COC co-prescription). Pregnancy contraindicated (theoretical feminisation of male fetus).

Standard trans-feminine antiandrogen in US at 100-200 mg/day alongside estradiol. Modestly reduces facial hair growth rate but rarely eliminates terminal follicles — laser/electrolysis remain needed for cosmetic clearance.

Cochrane Brown 2016; Endocrine Society Martin 2018 JCEM; Plovanich 2015.

Steroidal AR antagonist with progestogenic and gonadotropin-suppressive effects. Not FDA-approved in US; widely used in Europe/Canada/Australia for hirsutism (25-100 mg/d) and in trans-feminine HRT (historically 50-100 mg/d; now commonly 10-25 mg/d).

Other concerns: rare fulminant hepatitis at high doses, transaminase elevations, VTE (Diane-35 35 µg EE + 2 mg CPA: EMA 2013 review restricted first-line use).

Weill 2021 BMJ n37; EMA/ANSM 2020 review; Endocrine Society 2018.

Finasteride 2.5-5 mg/day reduces hirsutism F-G modestly (Cochrane SMD ~-1.0 vs placebo). Dutasteride 0.5 mg/day appears more effective (Lumachi & Rondinone 2003, n=54: dut ~6-point F-G reduction at 6 mo vs fin ~4-point, p<0.05). Not first-line; used when anti-androgens + COC inadequate. Pregnancy category X; contraception mandatory.

Lumachi 2003 PMID 12952360; Cochrane Brown 2016.

Suppress ovarian androgens (LH ↓) and raise SHBG (free T ↓). Anti-androgenic progestins (drospirenone, cyproterone, dienogest) outperform older progestins (levonorgestrel, norgestrel) on hirsutism endpoints. F-G reduction modest (~15-25% at 6-12 mo), less than spiro monotherapy in some trials. Endocrine Society first-line combination for moderate-severe hirsutism is COC + spiro.

Diane-35 (CPA 2 mg + EE 35 µg) widely used in EU/Canada/Australia; elevated VTE risk vs levonorgestrel COCs (OR ~1.5-2.0).

Endocrine Society 2018 JCEM; Cochrane Brown 2016; EMA 2013 Diane-35 review.

Leuprolide, triptorelin, goserelin suppress LH/FSH → ovarian androgen drop. Effective for severe hirsutism, especially with ovarian source, but induce reversible menopausal state (hot flashes, bone-density loss). Usually combined with "add-back" estrogen-progestogen to mitigate. Cost and injection burden limit routine use.

Heiner 1995 PMID 7539811; Endocrine Society 2018.

Modified Ferriman-Gallwey >8 (East Asian >6) defines hirsutism. Workup: total and free testosterone, DHEAS, 17-hydroxyprogesterone (to screen for non-classical CAH), prolactin, TSH. ACTH stim if 17-OHP borderline. Dexamethasone suppression if Cushing features. Imaging (pelvic ± adrenal) if rapid virilisation or total T >150 ng/dL (androgen-secreting tumor).

Hypertrichosis (non-androgen, often lanugo/vellus) is a different phenotype: congenital (lanuginosa, Ambras), paraneoplastic (lanuginosa acquisita), porphyria cutanea tarda, anorexia (starvation lanugo), drug-induced (minoxidil, cyclosporine, phenytoin, diazoxide, glucocorticoids), Becker nevus.

Endocrine Society hirsutism guideline 2018 JCEM; Trueb 2002 Dermatology.

Mechanism: Miramar Labs' 5.8 GHz focused microwave thermally destroys eccrine/apocrine glands in axillae; the hair-reduction protocol is the same device with different parameters. Melanin-independent — works on any hair colour. FDA-cleared (via 510(k), Aug 2015) for permanent reduction of axillary hair of all colours. Reported ~70% axillary hair reduction.

Weiss 2017 Dermatol Surg PMID 28005625; Miramar/Sientra product literature.

Topical 5-aminolevulinic acid (ALA) or methyl-aminolevulinate → protoporphyrin IX accumulation selective for pilosebaceous units, highest in anagen. Activated by red or blue light. Theoretically works on blonde/white/grey hair because mechanism is porphyrin-based, not melanin-based. Grossman 1995 conference abstract; Shin 2016 animal model.

Grossman 1995 Lasers Surg Med Suppl 7:44; Shin 2016 PMID 27504592.

Sebacia Microparticles (silica-core, gold-shell, PEG-coated) massaged into follicular infundibula then activated by Nd:YAG 1064. FDA 510(k) cleared Sept 2018 for mild-moderate inflammatory acne vulgaris only. Sienna SNA-001 silver photoparticle had a hair-removal 510(k) submitted Sept 2019; Sienna filed bankruptcy, assets acquired by Sebacia Dec 2019 for $1.7M. Sebacia itself wound down 2020-21 (Gerbsman Partners auction, bids due Jan 8 2021). Effectively unavailable. Historically interesting; practically gone.

FDA 510(k) K181518; Gerbsman Partners sale notice Nov 2020.

Combines broadband IPL with conducted bipolar radiofrequency — some energy deposition is melanin-independent, making these machines safer on darker skin at lower optical fluences. One blinded controlled trial: IPL+biRF 47.2% vs IPL alone 39.2% mean reduction after 2 sessions (p=0.004). Modest incremental benefit. Inferior to dedicated Nd:YAG on Fitz V-VI; inferior to alex/diode on optimal Fitz I-III dark coarse hair. Compromise device.

Sadick 2004 J Cosmet Laser Ther; Yaghmai 2005 PMID 16020204.

FDA 1998 position: "no statistically significant scientific data to support promotional claims of permanent or long-term removal of hair through use of the device." Hair is not a conductor; clamped-shaft devices cannot deliver meaningful current to the dermal papilla. 1985 FTC action against Removatron prohibited permanent-hair claims for AC tweezers; DC variants exploited the loophole, multiple subsequent FTC consent orders. Enforcement remains incomplete. The classic "too good to be true" category.

HairFacts (Andrea James regulatory summary); FDA/FTC case files.

Kalo, Ultra Hair Away, Stop Hair etc. Common actives: decapeptide-18 (actually a hair-growth promoter via Wnt/β-catenin — opposite direction), Capislow (nordihydroguaiaretic acid from Larrea divaricata), pea-shoot extract (Pisum sativum, more published for hair-growth indication). No independent RCTs of meaningful reduction beyond placebo.

Long-pulsed Nd:YAG 1064 is standard of care. Starting parameters Fitz V-VI: 20-40 ms pulse, 10-12 mm spot, fluence 24-40 J/cm², robust contact or cryogen cooling. Short-wavelength alex 755 / diode 810 burn Fitz V-VI unless fluence is dropped substantially. PIH is the commonest complication: <2% with calibrated Nd:YAG vs up to 19% with shorter wavelengths. PIH management: strict photoprotection, hydroquinone 2-4% (4-8 wk cycles), azelaic acid 15-20%, tretinoin, niacinamide, tranexamic acid (oral 250 mg BID or topical 3-5%).

Ibrahimi 2011 PMID 21519944; Battle 2002 PMID 14725660.

Endocrine Society 2018: COC first-line; add spironolactone 100 mg/day (or cyproterone where available) for moderate-severe; 5-ARIs second-line; eflornithine for face; GnRH agonist reserved for severe/refractory. Metformin no better than placebo on hirsutism score. Laser/IPL + medical > either alone. Durable response requires 6-9 months. Electrolysis for final cosmetic clean-up. Lifetime management for most patients.

Endocrine Society Martin 2018 JCEM; SOGC 2023 guideline 444.

• Areola / nipple: electrolysis safest. If laser, low-fluence Nd:YAG only — shorter wavelengths absorb in areolar melanin and risk PIH.
• Eyebrows / inside orbital rim: do not laser inside the bony orbit. Iritis, iris atrophy, uveitis, synechiae documented even with external shields. Intraocular corneal shields (Oculoplastik, Cox II) for brows outside the rim; electrolysis only for anything inside.
• Genital / perianal: Nd:YAG preferred for laser. HSV prophylaxis (valacyclovir 500 mg BID × 10-14 d) for known HSV-2. Fitz V-VI genital skin is particularly unforgiving.

Lin JAMA Ophthalmol; Shulman 2011 PMC3245195; Beeson 2002 PMID 11966791.

No demonstrated fetal harm from laser or electrolysis, but both routinely deferred as precaution. Eflornithine pregnancy category C (not recommended). Spironolactone contraindicated (theoretical feminisation of male fetus). Finasteride/dutasteride category X. Most providers defer non-essential hair removal until post-partum.

Required for scrotal-skin-inversion and penile-inversion vaginoplasty to prevent intravaginal hair growth, granulation tissue, infection, and stones. Surgeon-specific template — e.g., 1 inch around base of penis + all scrotal skin + 2.5 inches of perineum (penile inversion). Peritoneal pull-through and sigmoid variants have different requirements because the neovaginal canal composition differs.

Salibian/Zhang 2022 PMC9537259 (n=52, 44 full-depth)

• Electrolysis only: 24.3 sessions / 48.1 h / $5,161 avg / pain 6.9 / 91.7% needed anaesthesia.
• Laser only (eligible dark-hair patients): 8.1 sessions / 1.9 h / $962 / pain 4.4 / 33.3% needed anaesthesia.
• Both groups reached the pre-op clearance endpoint (<5 hairs regrowth / 2 months); laser far more efficient when hair colour allowed.

Timeline: 6-12 months pre-op active removal + 3-month confirmation wait = 9-15 month lead time. Final session ≥2 weeks before surgery. Nerve blocks (spermatic cord, lidocaine or bupivacaine) are standard for multi-hour electrolysis sessions on scrotal tissue.

Salibian/Zhang 2022 PMC9537259; MtF Surgery patient guide; Marci Bowers vaginoplasty prep.

Trans hair-removal culture was built across Susan's Place, Hairtell, `r/MtF`, `r/asktransgender`, and later `r/DrWillPowers`. The core message is consistent with the clinical evidence but operationally sharper: start earlier than you think, get the surgeon's exact map, use laser first when the beard is dark enough, and do not assume hormones will make established facial follicles irrelevant.

The emotional burden is also under-described in the medical literature. Community reports repeatedly emphasize that the hard part is not only pain; it is the visible stubble cycle, the need to grow hair between some electrolysis sessions, repeated swelling or scabbing windows, and the way insurance paperwork and provider scarcity can delay care even when the medical necessity is clear.

UCSF transcare hair-removal guideline; Hairtell transgender/electrolysis threads; Susan's Place vaginoplasty prep threads; current Reddit discussions retrieved 2026-04.

Laser 8-12+ sessions typically clears bulk of dark terminal hair; electrolysis handles residual blonde, grey, and hormonally-new hairs. Estrogen plus antiandrogen can slow facial-hair growth but rarely makes established terminal beard hair cosmetically irrelevant, so laser or electrolysis is still usually required. Full-face transfeminine electrolysis often still runs into triple-digit hours over 12-36 months, which is why communities treat provider continuity and realistic scheduling as major outcome variables.

Insurance and community reality (US): SOC-8 Statement 2.1 and Appendix E support hair removal from the face, body, and genital areas as medically necessary gender-affirming care, and Chapter 13 separately supports pre-op genital clearance. Actual payment remains uneven. Washington Apple Health and MassHealth are the clearest currently verified Medicaid examples; Oregon's current OHP documentation is still surgery-prep-focused; California and New York remain more plan- and implementation-dependent in the currently verified public materials.

WPATH SOC-8 Statement 2.1 / Appendix E; Washington HCA transhealth materials; MassHealth hair-removal guidance; Oregon OHA hair-removal authorization requirements.

Radial forearm flap or anterolateral thigh (ALT) flap donor sites need hair cleared from the urethral-tube area before harvesting — post-op hair in the neourethra causes stones and chronic infection. Typical lead: 30-80 hours electrolysis over 6-12 months. Some surgeons accept pre-op laser for dark-hair eligible patients; electrolysis is still usually needed for definitive clearance of finer hairs.

Aetiology: curly hair fibre + close shave (especially multi-blade, which cuts below the surface) → trans- or extra-follicular re-entry of sharp cut tip → foreign-body inflammatory papule. Affects ~45-85% of Black men; also any tightly-curled hair regardless of ancestry.

Conservative first: grow beard ≥1/4 inch (single best intervention); single-blade safety razor; with-the-grain strokes; pre-shave warm compress; barium-sulfide depilatory (Magic Shave) or thioglycolate (no below-surface sharp tip → no re-entry lesion); glycolic or salicylic acid daily peel; benzoyl peroxide adjunct.

Laser: long-pulse Nd:YAG 1064 nm is first-line for Fitz IV-VI. Ross 2002 JAAD — 2-session Nd:YAG significantly reduced papule counts. Smith 2009 (n=26, Fitz IV-VI) — 11.6 vs 30.1 papules treated vs untreated side. Battle 2021 (US service members, 74% Black) — 88% satisfied, 70% ≥75% lesion reduction, 96% able to shave again; PFB recurrence in 84% over time, so maintenance treatment typical. Eflornithine + Nd:YAG > Nd:YAG alone (Aboelsaad 2021).

Ross 2002 JAAD; Smith 2009 PMC2594258; Battle 2021; Aboelsaad 2021 PMID 33629488.

Chronic follicular inflammatory condition of the occipital scalp, predominately in Black men. Long-pulse Nd:YAG 1064 for papular-stage disease, with or without topical/intralesional steroid. 5-7 mm penetration targets follicle depth. Multiple small series (Esmat 2012, Umar 2013, 2018 prospective controlled trial). Surgical excision for late keloid-stage disease.

Esmat 2012 PMID 23588150; 2018 controlled trial PMID 29587518.

Long-pulse Nd:YAG 1064 reduces disease severity in Hurley I-II hidradenitis. Mahmoud 2010 JAAD — prospective controlled clinical + histopathologic study, improvement in lesion count, inflammation, severity scores. Xu 2011 JAMA Dermatol — histopathologic series confirming reduced follicular plugging. 2024 alexandrite RCT in JAAD Int showed similar benefit with alex on eligible skin types. 2025 systematic review summarises laser as adjunct.

Mahmoud 2010 PMID 19438670; Xu 2011 PMID 20855672; 2024 alex RCT JAAD Int.

FDA 2007 Public Health Advisory; Dermatology Times incident reports; product PIs.

Zimmer Cryo 6 — forced cold air (-30 °C), no consumables, doesn't interfere with the laser beam; ~3× cheaper than cryogen spray amortised. Contact sapphire plates built into most modern diode/alex devices. Candela DCD (cryogen R134a spray, ~30-100 ms spurt just before pulse) — precise, but consumable, and risk of superficial frostbite if misaligned. Ice pre/post — low-tech, widely used. Nerve blocks (infraorbital, mental) for full-face sessions from trans-specialty electrology practices.

The current practical pattern is three letters, not one: a surgeon letter for mapped pre-op fields when surgery is involved, a treating-clinician letter explaining diagnosis and prior failed measures, and a hair-removal-provider letter translating the plan into units, areas, and modality. Washington Apple Health and MassHealth now publish this logic explicitly for gender-affirming hair removal, while commercial payers still vary sharply by plan and network.

Aetna's base commercial policy remains narrow, explicitly covering a limited number of electrolysis or laser sessions for genital skin-graft preparation while treating broader hair removal as cosmetic unless plan language says otherwise. UnitedHealthcare's 2026 policy acknowledges the category but emphasizes the thin evidence base, which in practice means plan language and local provider billing competence determine more than abstract medical consensus.

Washington HCA transhealth program; MassHealth hair-removal guideline; Aetna CPB 0615; UHC 2026 Gender Dysphoria Treatment policy.